"COMPASS is a company that passionately cares about the development of novel therapies to tackle the mental health crisis facing society. I am truly inspired by the level of determination shown by the team to make a lasting difference for people who continue to suffer."

Gary Gilmour

Director of Preclinical Research

Gary runs the preclinical research programme at COMPASS.

Gary initially studied Pharmacology at the University of Glasgow before completing a DPhil in Neuroscience at the University of Oxford.  Gary has built his career in the pharmaceutical industry, most recently working for Eli Lilly as a Research Advisor in the Pain Discovery Group.  Gary has led discovery and novel target projects across a broad range of neuroscience indications, and has driven the establishment of pioneering techniques establishing preclinical proxies of BOLD imaging in behavioural studies.  His approaches to drug discovery place high emphasis on translational validation and establishing a deeper understanding of the biological substrates underlying different disease related symptoms.

"COMPASS is a company that passionately cares about the development of novel therapies to tackle the mental health crisis facing society. I am truly inspired by the level of determination shown by the team to make a lasting difference for people who continue to suffer."